ストックスクリーナーアプリを入手
103.09
0.76%
-0.79
アフターアワーズ：
103.09
前日終値:
$103.88
開ける：
$102.755
24時間の取引高:
1.29M
Relative Volume:
1.44
時価総額：
$24.78B
収益：
$3.13B
当期純損益:
$-381.72M
株価収益率:
-64.36
EPS:
-1.6017
ネットキャッシュフロー:
$-2.15B
1週間 パフォーマンス:
-0.05%
1か月 パフォーマンス:
+0.47%
6か月 パフォーマンス:
+11.95%
1年 パフォーマンス:
-0.45%
1日の値動き範囲:
$101.52
$105.00
1週間の範囲:
$101.52
$113.39
52週間の値動き範囲:
$81.20
$129.27
Biontech Se Adr Stock (BNTX) Company Profile
BNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
103.09 | 24.98B | 3.13B | -381.72M | -2.15B | -1.6017 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.90 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-05-29 | 開始されました | Goldman | Neutral |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-01-10 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-11-19 | 開始されました | Berenberg | Buy |
| 2024-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-08 | アップグレード | Goldman | Neutral → Buy |
| 2024-09-24 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-08-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-08-02 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-14 | 開始されました | Evercore ISI | In-line |
| 2024-02-23 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-05 | 開始されました | Oppenheimer | Perform |
| 2023-12-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-10-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-17 | アップグレード | Redburn | Neutral → Buy |
| 2022-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-17 | 開始されました | Cowen | Market Perform |
| 2022-07-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2021-12-16 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-08-11 | アップグレード | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-16 | ダウングレード | Redburn | Neutral → Sell |
| 2021-05-18 | 開始されました | Goldman | Neutral |
| 2021-05-11 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-08-03 | 再開されました | Berenberg | Buy |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 開始されました | H.C. Wainwright | Neutral |
| 2020-01-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-11-05 | 開始されました | Wolfe Research | Outperform |
| 2019-11-04 | 開始されました | Berenberg | Buy |
| 2019-11-04 | 開始されました | BofA/Merrill | Buy |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-11-04 | 開始されました | JP Morgan | Overweight |
| 2019-11-04 | 開始されました | SVB Leerink | Outperform |
| 2019-11-04 | 開始されました | UBS | Buy |
すべてを表示
Biontech Se Adr (BNTX) 最新ニュース
BioNTech Shares Under Pressure as Key Investor Exits - AD HOC NEWS
Allianz SE Buys 5,080 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run - Benzinga
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
BioNTech SE (BNTX) Stock Price, Trades & News - GuruFocus
BioNTech SE Reports Q3 2025 Financial Results - MSN
BioNTech’s Earnings Call: Progress Amid Challenges - MSN
BioNTech’s Promising Clinical Study: A New Hope for Advanced Solid Tumors? - MSN
BioNTech Faces Critical Earnings Test Amid Divergent Forecasts () - aktiencheck.de
BioNTech SE’s Promising Phase 3 Study on NSCLC Treatment: A Potential Game-Changer - TipRanks
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - MSN
BioNTech’s BNT116 Study: A New Hope for Advanced Lung Cancer? - MSN
BioNTech’s Promising PDAC Study: Market Implications and Progress - MSN
BioNTech’s Latest Clinical Study: A New Hope for Advanced Solid Tumors? - TipRanks
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
BioNTech’s Latest Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - TipRanks
Bristol-Myers Squibb and BioNTech’s New Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech Launch New Colorectal Cancer Study - TipRanks
BioNTech’s Promising Study on BNT113 and Pembrolizumab for Head and Neck Cancer - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game Changer - TipRanks
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
BioNTech’s Promising Phase 1/2a Trial: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s Promising Phase II Study on MIUC: A Potential Game-Changer? - TipRanks
BioNTech’s Promising Lung Cancer Study: A Potential Game Changer? - TipRanks
BioNTech’s BNT326 Study: A New Hope for Advanced Tumor Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech SE Launch New Study on Pumitamig for Triple-Negative Breast Cancer - TipRanks
Pfizer and BioNTech’s New Study on Variant-Adapted COVID-19 Vaccine for Children: What Investors Need to Know - TipRanks
BioNTech SE’s Promising Phase II Study on Advanced Solid Tumors - TipRanks
BioNTech SE’s New Study on PM8002: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Pfizer and BioNTech’s New Vaccine Study: A Potential Game-Changer for COVID-19 Prevention - TipRanks
BioNTech’s Latest Clinical Trial: A Potential Game-Changer in Breast Cancer Treatment? - TipRanks
BioNTech’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
Pfizer and BioNTech’s Innovative Vaccine Study: A Potential Game-Changer? - TipRanks
Sector Gamma AS Grows Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
DekaBank Deutsche Girozentrale Grows Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Clears Major Hurdle in CureVac Acquisition Process () - aktiencheck.de
Allianz Asset Management GmbH Acquires 2,815 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BioNTech Clears Final Hurdle for $1.25 Billion CureVac Acquisition () - aktiencheck.de
Aberdeen Group plc Grows Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Mirae Asset Global Investments Co. Ltd. Purchases 533 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Globe and Mail
Shell Asset Management Co. Buys 5,398 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Slow Capital Inc. Sells 3,415 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Biontech Se Adr (BNTX) 財務データ
収益
当期純利益
現金流量
EPS
1.20%
0.07%
大文字化:
|
ボリューム (24 時間):